Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu and currently employs 383 full-time employees. The company went IPO on 2019-05-31. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The firm is also engaged in the transfer of intellectual property. The firm mainly conducts its business in the domestic market.
02181.HK stock price ended at $0.51 on jeudi, after rising 0.00%
On the latest trading day Feb 12, 2026, the stock price of 02181.HK rose by 0.00%, climbing from $0.51 to $0.51. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.51 and a high of $0.51. Alongside this price increase, trading volume also rose by 18.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, -- shares were traded, amounting to a market value of approximately $2.1B.
Signaux Techniques de 02181.HK
Résumé des Signaux Techniques
Acheter des signaux 2
Signaux neutres 1
Signaux de vente 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
02181.HK présente actuellement 2 signaux d'achat et 4 signaux de vente. L'action est en tendance haussière depuis 12:00 AM, avec une variation totale du prix de -- pendant cette période. En général, les indicateurs techniques indiquent une tendance Sell à moyen terme.
Signaux haussiers/baissiers pour 02181.HK
Nous analysons les indicateurs clés comme les moyennes mobiles, le RSI, le MACD et le volume de transactions pour générer des signaux haussiers et baissiers pour 02181.HK, vous aidant à prendre des décisions d'investissement éclairées.